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Background
Thymidylate synthase (TYMS) is a homodimeric protein with identical subunits (molec-
ular weight for each unit ~35  kDa) and one of the most conserved protein entities in 
nature (Chu et al. 1991; Phan et al. 2001). It has long been well-known as a drug target, 
notably of 5-fluoro uracil (5-FU) and the anti-folate raltitrexed, for treatments of colo-
rectal cancer (Chu et al. 1991; Phan et al. 2001; Costi et al. 2005). Both subunits of TS 
contribute to each of the two active sites; however, it shows “half-of-the-site activity” 
i.e. conformational switching between active and inactive states, thus only one subunit 
being active at a time (Świniarska et al. 2010; Luo et al. 2011). It is a key enzyme in folate 
metabolic pathway—thereby an essential precursor for biosynthesis of DNA, RNA and 
protein (Arooj et al. 2013; Hardy et al. 1987). TYMS catalyses the de novo pathway for 
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Capecitabine, a fluoropyrimidine prodrug, has been a frequently chosen ligand for 
the last one and half decades to inhibit thymidylate synthase (TYMS) for treatment 
of colorectal cancer. TYMS is a key enzyme for de novo synthesis of deoxythymidine 
monophosphate and subsequent synthesis of DNA. Recent years have also seen the 
trait of modifying ligands using halogens and trifluoromethyl (–CF3) group to ensure 
enhanced drug performance. In this study, in silico modification of capecitabine with 
Cl, Br, I atoms and –CF3 group has been performed. Density functional theory has 
been employed to optimize the drug molecules and elucidate their thermodynamic 
and electrical properties such as Gibbs free energy, enthalpy, electronic energy, dipole 
moment and frontier orbital features (HOMO–LUMO gap, hardness and softness). 
Flexible and rigid molecular docking have been implemented between drugs and the 
receptor TYMS. Both inter- and intra-molecular non-covalent interactions involving the 
amino acid residues of TYMS and the drug molecules are explored in details. The drugs 
were superimposed on the resolved crystal structure (at 1.9 Å) of ZD1694/dUMP/TYMS 
system to shed light on similarity of the binding of capecitabine, and its modifiers, to 
that of ZD1694. Together, these results may provide more insights prior to synthesizing 
halogen-directed derivatives of capecitabine for anticancer treatment.
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the production of deoxythymidine monophosphate (dTMP), one of the three nucle-
otides which form thymine (a nucleic acid in DNA) and dihydrofolate from deoxyur-
idine monophosphate (dUMP) and 5,10-methylenetetrahydrofolate (mTHF) (Chu et al. 
1991; Peters et al. 2002; Salo-Ahen and Wade 2011). The process involves a cycle, where 
dietary folate is reduced to dihydrofolate and then to tetrahydrofolate (THF) by dihy-
drofolate reductase while D2NADPH supplying necessary hydrogen. Serine transhy-
droxymethylase converts THF to mTHF. Meanwhile, dUMP binds to a receptor site of 
TYMS—prompting a configurational change to create a binding site for mTHF. Trans-
fer of a methyl group to the uridine ring results in the formation of dihydrofolate and 
dTMP (Danenberg and Danenberg 1978; Santi et  al. 1974). Because of its pivotal role 
in synthesis of DNA, TYMS remains one of the important target proteins in cancer 
chemotherapy.
Capecitabine (N4-pentyloxycarbonyl-5-deoxy-5-fluorocytidine) is a fluoropyrimidine-
based novel oral prodrug designed by Miwa et  al. This drug received the approval by 
FDA (US Food and Drug Administration) in 1998 and has been in use as a ligand  for 
TYMS inhibition. A prodrugis an inactive chemical derivative of an active drug molecule 
which, after being administered specifically into the target cells or tumors, is converted 
to the desired form and ensures improved bioavailability. When delivered orally, capecit-
abine is absorbed through the intestinal wall of cells and converted to 5′-deoxy-5-fluoro-
uridinein a three-step sequential enzymatic pathway, which includes the last-step tumor 
selective reaction catalyzed by the tumor-associated angiogenic factor thymidine phos-
phorylase—eventually leading to transformation into 5-fluorouracil (5-FU). 5-FU has 
been known as the mainstream antifolate that inhibits TYMS. Entering the cell, 5-FU 
is converted to 5-fluorodeoxyuridine monophosphate (FdUMP) which, mutually with 
the methyl donor-reduced folate, forms a covalent stable ternary complex with TYMS, 
thus preventing thymidine synthesis in cells. In addition, its alteration into fluorouri-
dine triphosphate (FUTP) and fluorodeoxyuridine triphosphate (FdUTP) disrupts the 
function of RNA and DNA in tumor cells respectively (Stella et al. 1985; Papamichael 
2000; Etienne et al. 2004; Longley et al. 2003; Park et al. 2002; Miwa et al. 1998; Ishikawa 
et al. 1998). The drawback of direct administration of 5-FU due to primary and second-
ary resistance and its potential toxicity to normal, non-tumored cells, however, has been 
a matter of concern. 5-FU undergoes rapid metabolic change by dihydropyrimidine 
dehydrogenase (DPD) in the mucosa of the gastrointestinal tract and the liver—limit-
ing its oral bioavailability. In addition, adverse side-effects during its application—diar-
rhea, nausea and cardiovascular complexities for instance, have been reported (Mader 
et al. 1998; Saif 2009; Abou and Fadl 2009). Contrariwise, capecitabine is well-tolerated 
and enhances drug concentration at the tumor site, avoids complication associated with 
venous access and reduces cytotoxicity. Infact, stage III trials for treatment of colorectal 
cancer using capecitabine have been undertaken and shown markedly superior results, 
compared to 5-FU, with improved safety profiles (Miwa et  al. 1998; Scheithauer et  al. 
2003; Schmoll and Arnold 2006).
In governing the mechanisms responsible for diverse ligand–protein complex systems 
such as the one mentioned above, non-covalent intermolecular forces play a pivotal 
role. Elucidation and quantification of non-covalent forces are central to pharmaceuti-
cal drug-design and lead optimization. Important non-covalent interactions include 
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hydrogen bonding, electrostatic interactions, stacking interactions (cation–pi, anion–pi 
or pi–pi), van der Walls forces, and hydrophobic interactions (Meyer et al. 2003; Cerný 
and Hobza 2007; Dougherty 2007; Wheeler and Bloom 2014; Wheeler 2011; Varma 
et  al. 2010). Recent years have witnessed the importance of non-covalent interactions 
involving halogen atoms, otherwise termed as halogen bonding, due to their intriguing 
chemical features. Halogen bonds have been identified in many of biological low-mass 
compounds and in complexes of biomolecules with halogenated ligands. Halogen atoms 
can either function as electrophilic species or as nucleophilic Lewis bases and display 
anisotropic charge distribution along the region of a C–X bond with an equatorial dis-
tribution of negative and positive charges—thereby creating what is called a σ-hole. A 
σ-hole maintains a diminished electron density site and entices an electronegative site 
of another molecule to interact. Such cases occur, especially those with larger atomic 
radii (chlorine, bromine and iodine) (Lu et al. 2009, 2012; Sirimulla et al. 2013). On the 
other hand, drug candidates containing fluorine show increased metabolic stability and 
membrane permeation, hence use of them has become commonplace. The small-size 
and very high electronegativity of fluorine attribute to its eccentric behaviors, which 
in turn contribute to its versatile interactions in biomolecular receptor-ligand moieties 
(Hagmann 2008; Smart 2001; Zhou et al. 2009).
This in silico study focuses on quantum mechanical and molecular docking analysis 
of thymidylate synthase (TYMS) against capecitabine and its halogenated derivatives, 
modified by trifluoromethane (–CF3), Cl, Br and I, to investigate compelling non-cova-
lent interactions in order to attain a deeper understanding and interpret the core charac-
teristics of such receptor-ligand synergy. In-silico approach, computer-aided drug design 
(CADD) in other words, has brought about a major revolution to facilitate the design 
and discovery of novel therapeutic solutions (Kapetanovic 2008). CADD has been uti-
lized in diverse ways—choosing the most exact ligands and their target proteins from 
digital repositories such as DrugBank (Wishart et al. 2006), PubChem (Wang et al. 2009) 
or PDB (Berman et al. 2002), using softwares adept in sophisticated quantum mechani-
cal calculations and 3-D computer graphics to model and/or manipulate potential inhibi-
tors, carrying out molecular docking in order to foresight energetically favorable binding 
sites and interactions among the lead-candidates and target molecules with acute phys-
icochemical and pharmaceutical details (Koutsoukas et  al. 2011; Kapetanovic 2008; 
Tang et al. 2006; Song et al. 2009; Joseph-Mccarthy 1999). Discovery and marketing of 
a drug on average require around 7–12  years of research and cost from US$800 mil-
lion to US $1.2 billion; however, CADD has been successful in minimizing the lengthy 
trial-and-error research cycle and gigantic costs involving drug discovery (Kapetanovic 
2008; Tang et al. 2006). In this work, thermo-chemical and molecular orbital calculation 
for the drug candidates were performed. Each of the ligand molecules was subjected to 
flexible and rigid docking to elucidate binding energies, binding sites and characteris-
tics of various non-bonding interactions among those complex receptor–ligand environ-
ments. In addition, the results have been compared to the previously determined crystal 
structure of ZD1694–dUMP–TYMS complex at 1.9 A resolution to identify the degree 
of superposition of the presently observed systems to that of a resolved one (Phan et al. 
2001).
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Computational methods
Optimization of drugs using quantum mechanical calculations
Quantum mechanical calculations were performed using Gaussian 09 program-suit 
(Gaussian 09 Revision 2009). The structures of capecitabine was fully optimized utilizing 
density functional theory employing B3LYP/MidiX level of theory. The basis set is ini-
tially developed from the Huzinaga MIDI basis and more compatible for molecules with 
halogen atoms (Easton et al. 1996). The initial structure of capecitabine was manipulated 
replacing fluorine with –CF3, Cl, Br and I; the modified compounds, labeled from D1–
D4 sequentially (Figs. 1, 2), were then optimized using the same level of theory. Internal 
electronic energy, enthalpy, Gibbs free energy and dipole moment were investigated for 
each of the molecules. Energetics data of a system exploiting Gaussian 09 are produced 
by solving traditional thermodynamic and quantum mechanical equations. Contribu-
tions from each of translational, rotational, vibrational and electronic motions are con-
sidered to estimate the thermodynamic parameters of a system. Sum of electronic and 
thermal energies in a molecule is represented by the following equation (Gaussian 09 
Revision 2009)
(1)Sum of electronic and thermal energies = ε0 + Etot
Fig. 1 Optimized structure of capecitabine and its halogenated derivatives (D1) generated at B3LYP/MidiX 
level of theory
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where εo is the total electronic energy for a given system and Etot is the correction to 
internal thermal energy when Etot = Et + Er + Ev + Ee. Similarly,
(2)Sum of electronic andthermal enthalpies = ε0 +Hcorr
(3)Sum of electronic and thermal free energies = ε0 + Gcorr
Fig. 2 Optimized structure of halogenated derivatives (D2, D3 and D4) generated at B3LYP/MidiX level of 
theory
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where Hcorr and Gcorr are the thermal corrections for enthalpy and Gibbs free energy for 
the given system respectively.
Frontier molecular orbital calculations were also conducted using the same level of 
theory. Considering the correlation of ionization potential (I) with HOMO and electron 
affinity (E) with LUMO according to Koopmans theorem, hardness (η) and softness (S) 
of the drugs were calculated according to the following equations (Pearson 1986)
Preparation of protein
Crystal structure of thymidylate synthase (TYMS) was collected from Protein Data 
Bank (PDB, ID: 1HVY; Chain A) (Fig. 3). Prior to docking, heteroatoms, lipids and water 
molecules were removed from the crystal structure using PyMol (version 1.3) (DeLano 
2002). Geometry and energy minimization of the crystal structure were carried out with 
Swiss-PDBViewer (version 4.1.0) employing GROMOS96 force field (Guex and Peitsch 
1997; Scott et al. 1999). The ligand and protein structures were saved as .pdb files.
Binding site and docking
The active binding pocket of TYMS was predicted using CASTp (Dundas et al. 2006), 
which found the largest pocket area and volume to be 1347.7 Å2 and 1976.3 Å3 respec-
tively (Additional file 1: Figure S1 provides with some of the most favorable pocket area 
and volume alongside the amino acid residue chains. The colored region in the protein 
structure represented largest pocket area and volume). These information were used to 
generate the grid boxes during molecular docking.
Molecular docking is a method that predicts preferred orientation of a compound 
bound to a second during the formation of a stable complex and finds its frequent appli-
cation in in silico pharmaceutical design. Current methods of docking include pose pre-
diction, using docking algorithms and energy-based scoring functions that identify the 







Fig. 3 Crystal structure of thymidylate synthase (TYMS)
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active sites of a target protein. Lower free energy means better ligand–protein binding 
(Thomsen and Christensen 2006; Gschwend et al. 1996; Kroemer 2007). Two types of 
docking algorithms are most common: flexible and rigid. In flexible docking, either one 
or both of the molecules involved in binding are considered as flexible objects, whereas 
rigid docking imposes conformational restriction on both the ligand and protein, 
thereby considering them as rigid solid objects (Zhou et al. 2007; Halperin et al. 2002). 
In the current work, both flexible and rigid docking for each of the ligand–protein enti-
ties were performed using Autodock Vina (Trott and Olson 2010). TORSDOF was set 
for all the ligands followed by the conversion of all rotatable bonds into non-rotatable 
during rigid docking. While performing flexible docking, ligand molecules were kept 
flexible and the protein was kept rigid. The grid boxes were constructed in such a man-
ner that it covered the colored volumes corresponding to the binding pockets identified 
in Additional file 1: Figure S1. For both flexible and rigid docking, the dimensions of grid 
boxes were chosen as follows: 54.6895, 43.2718 and 54.3972 Å towards X, Y and Z co-
ordinates respectively. Detailed analysis of the residues involved in non-covalent interac-
tions between the ligands and protein was explored using Accelyrs Discovery Studio 4.1 
(2013) and LigPlot+ (version 1.4.5) (Laskowski and Swindells 2011).
Pharmacokinetic parameters
AdmetSAR online database has been utilized to generate the pharmacokinetic param-
eters related to drug absorption, metabolism and toxicity for the parent drug and its 
modifiers (Cheng et al. 2012). SDF (Structure Data File) and SMILES (simplified molec-
ular-input line-entry system) strings were utilized throughout the generation process.
Results and discussion
Electronic and thermodynamic behavior of capecitabine and its derivatives
The current work has employed the equations mentioned in “Optimization of drugs 
using quantum mechanical calculations” section to produce thermochemical data that 
predict the energetic availability and flexibility of capecitabine and its halogenated deriv-
atives, as depicted in Table 1. Exchange of F in the initial structure with bioisosteres –
CF3, Cl, Br and I saw a gradual increase in the negative value of electronic and thermal 
energies, enthalpy and free energy, hence suggesting energetically and configurationally 
more preferable trifluoromethylated, chlorinated, brominated and iodinated molecules. 
Table 1 Stoichiometry, electronic energy, enthalpy, Gibbs free energy (in Hartree) 
and dipole moment (in Debye) of Capecitabine and its halogenated derivatives










Capecitabine C15H22FN3O6 −1299.926 −1299.925 −1300.009 6.6677
D1 C16H22F3N3O6 −1528.935 −1528.933 −1529.023 5.1524
D2 C15H22ClN3O6 −1651.218 −1651.217 −1651.301 5.3633
D3 C15H22BrN3O6 −3755.199 −3755.198 −3755.283 6.1689
D4 C15H22IN3O6 −8083.324 −8083.323 −8083.410 6.1851
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To be specific, Br and I-substituted capecitabine molecules (D3 and D4) showed marked 
changes in the thermochemical data, in contrast to that of –CF3 and Cl-substituted ones 
(D1 and D2), suggesting greater atomic radii—halogen substituents allowing the modi-
fied drugs become more stable.
Dipole moment is a useful parameter in the study of drug-receptor systems and plays 
a significant role for the formation of hydrogen bond in biological systems (Lien et al. 
1982). The numerical value of dipole moment was highest for capecitabine. As listed 
in Table 1, high electronegativity of fluorine contributed to the overall high molecular 
dipole moment in capecitabine—partial charge on fluorine being −0.298 a.u., whereas 
the three fluorine atoms in –CF3 modified molecule D1 showed even more electronega-
tivity, ranging from −0.305 to −0.310 a.u. but a relatively overall lower dipole moment 
value. Partial charge for iodine in the iodinated structure D4 was found to be +0.148 
a.u. and the value of molecular dipole moment seemed to be relatively higher, indicating 
relatively higher polarity for D4 (the partial charge maps of capecitabine and its deriva-
tives are provided from Additional file 1: Figure S2).
Frontier molecular orbitals
Frontier orbitals (FO) are general terms used to denote both highest occupied molecular 
orbital (HOMO) and lowest unoccupied molecular orbital (LUMO). Frontier orbitals’ 
energy values are important to determine chemical reactivity and the extent to which 
a drug interacts with a particular receptor. Even, energy of HOMO along can be a piv-
otal determinant to find a relationship between a class of drug’s activity and their elec-
tronic configuration, as reported by Snyder et al. (Snyder and Merril 1965). The energy 
gap between HOMO and LUMO predicts of a molecule’s kinetic and chemical stability. 
Larger FO gap concords with high kinetic stability, but low chemical reactivity, as it is 
energetically unfavorable for an electron to have it elevated from a low-energy HOMO 
to a relatively high-lying LUMO (Aihara 1999; Hoque et al. 2013).
Pictorial views of HOMOs and LUMOs of capecitabine and its four derivatives are 
shown in Additional file  1: Table S1. Frontier orbital energy gap in capeciabine was 
found to be 0.1778 a.u.; values for the four derivatives ranged from 0.1770 to 0.1889 a.u. 
(Table 2). The iodinated derivative D4 showed the lowest energy gap among the deriva-
tives, 0.1770 a.u., which is even lower than the initial structure—hence enhanced soft-
ness, least hardness and high chemical reactivity. The –CF3 incorporated structure, on 
the other hand, revealed that it’s energy gap was the most unfavorable one in the group 
towards chemical reactivity.
Table 2 Energy of  HOMOs, LUMOs (a.u.), orbital gap, hardness and  softness of  Capecit-
abine and its derivatives
Ligands εHOMO εLUMO Orbital Gap Hardness Softness
Capecitabine −0.2394 −0.0616 0.1778 0.0889 11.24
D1 −0.2447 −0.0558 0.1889 0.0944 10.59
D2 −0.2379 −0.0573 0.1801 0.0901 11.10
D3 −0.2327 −0.0543 0.1784 0.0892 11.21
D4 −0.2316 −0.0546 0.1770 0.0850 11.76
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Molecular docking: binding energy of the receptor‑ligand systems
Table  3 lists the active site free energies of binding for each of the current receptor-
ligand systems and shows a comparison between the binding energy values obtained via 
flexible and rigid docking for each of the entities. The interaction energy for each of the 
ligand atoms is calculated for all the possible binding sites—discredited through a grid 
box—of the receptor, resulting in multiple values of binding energies for each system. For 
instance, flexible and rigid docking for each of the capecitabine-TYMS entities produced 
total eighteen possible energy values. However, we have chosen the values correspond-
ing to the second pose of the ligands as they tend to superimpose most appropriately on 
ZD1694—as we shall see in the latter sections. Binding energies for capecitabine-TYMS 
interactions of −7.1 and −8.8 Kcal  mol−1 for flexible and rigid dockings respectively 
demonstrated significant deviation into energy values. The modified molecules fol-
lowed the same trend as well. Flexible docking of D1–D4 against TYMS showed binding 
energy values from −8.0 to −7.4 Kcal mol−1, when rigid docking showed values from 
−9.5 to −8.2 Kcal  mol−1. The trifluoromethylated and chlorinated ligands possessed 
the two most negative energy values among the group, making them favorable modified 
derivatives than the other two. 
Non‑covalent interactions within the receptor–ligand systems
Crystal structure of ZD1694/dUMP/TYMS complex, in the earlier researches of Phan 
et al. confirmed the fact that a Cα–S and a O–H covalent bonding at Cys195 and His196 
of hTYMS are involved during the transformation of dUMP to dTMP (Phan et al. 2001). 
ZD1694 in the complex acts as a competitive binder against antifolate THF and inhib-
its the transformation required for DNA synthesis. The local environment of ZD1694/
dUMP/TYMS in their work showed a direct N–H–O contact between ZD1694 molecule 
and Asp218 as well as Gly222. The local environment, with all hydrophobic contacts 
being taken into consideration, has been regenerated for the purpose of this work—as 
depicted by Additional file  1: Figure S4. Possible non-covalent interactions analogous 
to the most negative free energies of binding in capecitabine-TYMS complex have also 
been shown in Table  4, a thorough checking of which elucidates that flexible docking 
provides with more interaction sites—compared to that of rigid docking. Moreover, 
further comparison between Capecitabine/dUMP/TYMS and ZD1694/dUMP/TYMS 
complexes shows the local environment to be nearly identical in case of flexibly docked 
Table 3 Free energy of  binding values (Kcal  mol−1) for  ligand-TYMS systems obtained 
from flexible and rigid docking
Systems Free energy of binding
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molecules. For instance, non-bonding hydrophobic contacts surrounding ZD1694 in the 
regenerated structure involved the following amino acid residues—Lys77, Phe80, Gly87, 
Ile108, Gly222, Phe225, Tyr 258 and Met311. On the other hand, flexibly docked capecit-
abine showed hydrophobic contacts involving Arg78, Val79, Phe80, Ile108, Leu221, 
Gly222, Phe225 and Met309; interaction sites are found completely different, however, 
in the rigid-docked molecule. As Fig.  4 would suggest, ZD1694 and flexibly docked 
capecitabine are well superimposed on each other-taking into account that the geometry 
of the latter here resembles only one of the nine poses—when the rigidly docked drug 
is significantly away. The case is same for the modified derivatives where rigidly docked 
Table 4 Comparison between  the non-covalent interactions between  Capecitabine 
and TYMS from flexible and rigid docking
Systems Non‑covalent interactions
Flexible docking Rigid docking










O–H–O Arg78 Hydrogen 2.31 O–H–N Val62 Hydrogen 3.05
O–H–C Val79 Carbon 2.67 C–C–S Cys180 Alkyl 3.61
O–H–N Phe80 Hydrogen 2.83 Alkyl–alkyl 
Leu198
Alkyl 3.69
O–H–C Ile108 Carbon 2.80 F–C–O Gly211 Halogen 3.35
Alkyl-π Ile108 Alkyl-π 5.45 F–O Leu212 Halogen 2.85
Alkyl-π 
Leu221
Alkyl-π 4.47 F–H–C Tyr213 Carbon 2.84
F–O Leu221 Halogen 3.26 C–H–O 
Leu252
Carbon 2.87








Fig. 4 Superposition of a Capecitabine and b D1 (trifluoromethylated ligand) on the ZD1694/dUMP/TYMS 
crystal structure resovlved at 1.9 Å. Green, red and purple molecules indicate ZD1694, flexibly docked and 
rigidly docked structures respectively
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ligands are observed not to superimpose on the crystal structure of ZD1694. Some more 
evidences will be found in Additional file 1: Figure S5, where the non-bonding interac-
tions involving rigid ligands have been shown. We, therefore, shall mostly focus on the 
non-bonding interactions involving flexibly docked ligands.
The nature of the non-bonding interactions varied from conventional hydrogen bond-
ing to stacking interactions, donor–donor and weak van der Walls interactions. For 
instance, in capecitabine/dUMP/TYMS, F–O and F–H–C halogen bonding at Leu221 
and Gly222 occurred. Rigid docking, however, predicted such interaction at Leu212. 
Here it is worth mentioning that despite reports suggested that halogen atoms with par-
tial positive charges take part in halogen bonding more frequently, electronegative fluo-
rine atoms in these cases were observed to form such interaction (Politzer et al. 2007). 
Phe225 was found to donate its π-electrons cloud towards the alkyl chain and the carbon 
attached to F of the drug, thus forming multiple π-stacking interactions. Here the phenyl 
residue shifts away from the ligand compared to that of ZD1694-Phe225 interactions—
as the distance increases to 4.71 from 4.50 Å. A sulphar interaction occurs at Met309 
with a bond distance 4.88 Å. Rigid docking, however, shows no interaction at the periph-
erical amino acid residues to Met311. An alkyl–alkyl weak interaction, however, occurs 
at Leu198—which is close to the Cys195 and His196. As observed comparing the inter-
action listed in Table  4, key interactions between TYMS side chains and ZD1694 are 
mostly, if not entirely, preserved in the flexibly docked capecitabine. The preservation 
continues in the modified structures as well as we shall see in the upcoming discussions.
The value of trifluoromethyl (–CF3) group for its pharmacological activity has been 
acknowledged since the 50’s of last century. The widespread use in pharmaceutical prod-
ucts has been witnessed in recent years due to its unique chemical and physiological sta-
bility and the fact that –CF3 group is lipophilic in nature—an important determinant for 
increasing the solubility of drugs and letting it penetrate through cell membrane more 
easily (Yale 1959; Ji et al. 2011). Flexible docking showed that like capecitabine, a fluo-
rine atom (F15) of the –CF3 group formed 2.82 Å long halogen bond with Leu221 and 
an F–C interaction with Gly222. Another F atom demonstated an anion-π stacking with 
the delocalized electron cloud of Phe225 (Fig.  5). A π-alkyl interaction at Trp109 was 
observed here—analogous to the interaction in ZD1694 complex. Lys77 was found to 
interact at the O of furan ring of the chlorinated derivative D2. Likewise, the halogen 
atom was found to form stacking and alkyl interactions with variable bond distances at 
Phe80 and Ile108. A π–π stacking was observed at Phe225 as well (Fig.  5). Nature of 
the residual environment surrounding the brominated ligand D3 was merely identical 
to D1 and D2—except Br forming an alkyl interaction at Ile108 as shown by the types of 
non-bonding interactions and the corresponding bond distances at (D1–D4)-TYMS in 
Table 5 (Additional file 1: Figure S3 illustrates the non-bonding scenario of D3 and D4 
with TYMS). Figure 6 illustrates a more rigorous view of the interactions, including the 
hydrophic binding sites at the periphery, of capecitabine, D1 and D2 ligands, as these 
three molecules are closer with respect to the binding energy values to one another. 
In an article published in 2009, Mairal et al. investigated the potential role of iodine in 
inhibiting Transthyretin Fibrillogenesis in which they discussed on the binding pockets 
of Transthyretin (TTR) that could accommodate iodine; using Diflusinal and its deriva-
tives as model compounds, they showed that iodine-inserted binding compounds could 
Page 12 of 18Rahman et al. SpringerPlus  (2016) 5:146 
Fig. 5 Non-covalent interactions among a Capecitabine-TYMS, b D1 (trifluoromethylated)-TYMS and c D2 
(chlorinated)-TYMS generated by discovery studio
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become crucial in inhibiting TTR activities for treatment of TTR-related amyloidosis 
(Mairal et al. 2009). Some other recent researches have also focused on pharmaceutical 
utilities of iodinated drugs (Barattin et al. 2010; Bois et al. 1998). The thermodynamic, 
frontier orbital and binding affinity data suggested good energetic availability of com-
pound D4. Same as the D3 derivative, flexible docking produced halogen-alkyl interac-
tions with Ile108 (bond-length 5.18 Å). Partial positive charge of iodine, evidenced by 
Fig. 6 Non-bonding and hydrophobic binding sites (flexible docking) involving a Capecitabine, b –CF3 
modified (D1) and c chlorinated derivative (D2) with TYMS
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partial charge map of D4 (Additional file 1: Figure S2), might have been a factor behind 
such interactions. As Table 5 suggests, D4 shows similar types of interactions with the 
same amino acids compared to its counterparts, with the bond types varying among 
hydrogen bonding, alkyl interactions and π-stacking.
Pharmacokinetic properties of the drugs
Inhibition constant Ki of all the drugs have been calculated using the equilibrium 
E + I ↔ EI, where E is the enzyme and I is the inhibitor molecule (the reference concen-
trations for all the entities have been considered 1 mol L−1 for the calculations) and the 
relationship
where ln Kb = −�G/RT, �G = free energy of binding and presented in the last row of 
Table 6. All of the drugs are non-carcinogenic, according to the ADME (absorption, dis-
tribution, metabolism, and excretion) analysis and possess a class III acute oral toxicity. 
The LD50 values also support the level of the acute toxicity, as they reveal good amount 
of tolerance against oral toxicity. This means that the drugs are relatively safer for oral 
delivery, and the –CF3 modified drug is the safest in the group—as seen by the LD50 val-
ues depicted in Table 6. The drugs are supposed to be absorbed without much complex-
ity as the human intestinal absorption was found positive for all the ligands (Shen et al. 
2010). All the drugs are P-glycoprotein non-inhibitor, when the probability is higher for 
the parent and –CF3 modified ligands. Inhibition of P-glycoprotein affects negatively a 
drug’s bioavailability and the extent of drug metabolism and intestinal absorption (Broc-
catelli et  al. 2011). The drugs do, however, show a positivity considering blood brain 
barrier, predicting that the drugs will go through the BBB. Adverse drug–drug interac-
tions and severe cardiac side effects can be avoided with capecitabine and the modified 
ln Kb = − ln Ki,
Table 6 Selected pharmacokinetic parameters of capecitabine and its derivatives
Probability values related to each of the parameters are given in the parenthesis
Parameters Capecitabine D1 D2 D3 D4
Blood brain 
barrier
+ (0.6064) + (0.5585) + (0.5248) + (0.5162) + (0.5000)
Human intestinal 
absorption









































III III III III III
Rat acute  
toxicity, LD50 
(mol/kg)
2.4690 2.4907 2.4453 2.4229 2.4365
Ki at 298 K (nM) 3116.86 635.71 753.50 1242.24 1834.69
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molecules, as the molecules are both CyP450 2C9 and hERG non-inhibitor (Shen et al. 
2010; Wang et al. 2012; Cheng et al. 2011).
Conclusion
Halogenation in capecitabine contributed to changes in its physicochemical properties. 
Thermodynamic calculation demonstrated the stability of capecitabine and its modi-
fied derivatives (D1–D4). Free energy and entropy estimation revealed relatively higher 
negative values, particularly for brominated and iodinated moieties (D3 and D4). The 
drug molecules were polar in nature confirmed by calculation of dipole moment. Fron-
tier orbital calculations revealed increased hardness for the –CF3 modified drug D1 and 
increased softness for the iodinated drug D4; moreover, softness values of the drugs, 
except fluorine, followed an increasing trend with the substitution of halogens of greater 
atomic radii. The –CF3 modified ligand was found to possess the most negative bind-
ing energy value. Molecular docking, both flexible and rigid, exposed the free energies 
of binding for each ligand–TYMS interaction, when in each case the value obtained by 
rigid docking was found slightly more negative than that obtained by flexible docking. 
However, the flexibly docked ligands could be superimposed better on ZD1694 within 
the crystal structure of TYMS, when rigidly docked molecules showed inconsistency in 
binding to the proper active sites. Docking identified wide-range non-bonding interac-
tions among the atoms of the drugs and amino acid units of TYMS. Flexible docking, 
for each ligand–receptor systems, revealed significant halogen interactions as well. Such 
compilation of information may prove worthwhile for more cost-effective and precise 
drug-designing and/or manipulation for TYMS inhibition.
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